David Kreimer

Fondatore presso MSM Protein Technologies, Inc.

Health Technology

Profilo

David Kreimer has founded a company called MSM Protein Technologies, Inc. in the year 2005.
At MSM Protein Technologies, Inc., Dr. Kreimer holds the titles of President, Chief Operating Officer & Director.

Posizioni attive di David Kreimer

Società	Posizione	Inizio
MSM Protein Technologies, Inc. MSM Protein Technologies, Inc. Pharmaceuticals: MajorHealth Technology MSM Protein Technologies is an early drug development company that specializes in antibody drug discovery against integral membrane proteins. MSM Protein Technologies is based in Waltham, MA and was founded in 2005 by Davis Farmer, Eldar Kim, and David Kreimer. The private company has a solid record of successful partnerships with big pharma companies in drug discovery and development programs. The company's pipeline includes a number of first-in-class pre-clinical stage antibodies targeting several GPCRs, mainly focused on immunologic and oncologic diseases such as blood cancers, solid tumors, autoimmune diseases, and respiratory diseases.	Fondatore	01/01/2005

Tutte le posizioni attive di David Kreimer

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di David Kreimer

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
MSM Protein Technologies, Inc. MSM Protein Technologies, Inc. Pharmaceuticals: MajorHealth Technology MSM Protein Technologies is an early drug development company that specializes in antibody drug discovery against integral membrane proteins. MSM Protein Technologies is based in Waltham, MA and was founded in 2005 by Davis Farmer, Eldar Kim, and David Kreimer. The private company has a solid record of successful partnerships with big pharma companies in drug discovery and development programs. The company's pipeline includes a number of first-in-class pre-clinical stage antibodies targeting several GPCRs, mainly focused on immunologic and oncologic diseases such as blood cancers, solid tumors, autoimmune diseases, and respiratory diseases.	Health Technology